AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04607954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT04723498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: screening questionnaire
Description: Fill in screening questionnaire
Study NCT04607954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Given IV
Study NCT01796561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive leaf extract liquid
Description: Commercially available polyphenol-rich olive leaf extract liquid
Study NCT00329238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Dabigatran 150 mg BID (twice daily)
Study NCT00329238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin dosed individually to maintain INR 2.0-3.0
Study NCT00160290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: 15 mL / 12 hours
Study NCT00160290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plantago ovata
Description: 3,5 g / 12 hours
Study NCT02528929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten-free diet
Description: Patients with IBS-D will commence a gluten-free diet for 6 weeks following dietetic input. They will be informed they do not have coeliac disease. They will however be blinded to whether or not they have any markers of at-risk serology. They will self-complete validated questionnaires over 6 weeks. Any subjects who opt to continue with a gluten-free diet thereafter of their own volition will be kept under observation as per routine clinical care.
Study NCT02358174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemorrhoidectomy
Description: Grade III and IV patients were treated with surgery according to Milligan-Morgan (Milligan-Morgan laser optical fibers variant) procedure.~All patients will perform blood sampling for MMPs and NGAL plasma levels evaluation
Study NCT02358174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: blood sampling for MMPs and NGAL plasma levels evaluation (ELISA test)
Study NCT05148936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVID-19 Testing Home-based (Aim 1)
Description: Implementation of Antigen and PCR testing at participant homes
Study NCT02358174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tissue sampling
Description: tissue sampling for MMPs and NGAL tissue levels evaluation (Western Blot)
Study NCT04505462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic diet
Description: A special healthy diet for dialysis patients
Study NCT03282682 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: The participants perform strength training sessions two times per week for 12 weeks. Each training session include 5-minute general dynamic warm-up followed by progressive strength training with exercises for the entire body. The strength exercises are performed with free weights and on machines. The training program consist of 6 exercises for upper and lower body at an intensity of 60-80% (8 - 12RM: the load that induces technique failure in eight or twelve repetitions) of one-repetition maximum and takes approximately 60 minutes. The exercises performed are: leg press, split squats, bench press, knee extension, knee flexion, seated cable rows, seated cable pull downs, dumbbell bench press, incline dumbbell bench press.
Study NCT03282682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength training
Description: The participants perform strength training sessions two times per week for 12 weeks. Each training session include 5-minute general dynamic warm-up followed by progressive strength training with exercises for the entire body. The strength exercises are performed with free weights and on machines. The training program consist of 6 exercises for upper and lower body at an intensity of 60-80% (8 - 12RM: the load that induces technique failure in eight or twelve repetitions) of one-repetition maximum and takes approximately 60 minutes. The exercises performed are: leg press, split squats, bench press, knee extension, knee flexion, seated cable rows, seated cable pull downs, dumbbell bench press, incline dumbbell bench press.
Study NCT06185283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: panoramic x-ray
Description: Long cone paralleling technique and a film holder designed specifically for implant imaging were used for intraoral radiograph. To maintain the same film- implant distance and cone implant distance, a modification were carried out for the film holder. This modification is a hole drilled exactly above the implant fixture so the distance were maintained during subsequent film exposures. Through this modification, standardized radiographs were achieved.
Study NCT02981420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety planning
Description: Safety Planning Intervention. This brief one-session intervention, based on cognitive behavioral principles, is designed to help individuals identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of suicidal behavior. In youth who also report nonsuicidal self-injurious behavior (NSSI), the safety plan will address both suicidal and nonsuicidal behavior. The plan helps youth identify possible triggers to SI/crisis including self-monitoring of suicidal thoughts, feelings, and behaviors; advance planning to remove lethal means; determine distress tolerance/emotion regulation skills that may be helpful; identify accessible social supports to target hopelessness/sense of isolation; reinforce the commitment to seek treatment; and, how and where to access emergency care.
Study NCT02973698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: chin-down posture maneuver
Description: it was performed the training of Chin-down postural maneuver with saliva and water. Besides, the subjects received instructions regarding feeding.
Study NCT02973698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Orientations about swallowing
Description: The instructions about feeding were performed. The individuals received all the instructions on a written document.
Study NCT05148936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Testing Mobile (Aim 1)
Description: Implementation of Antigen and PCR testing at mobile test sites
Study NCT02973698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention will do
Study NCT05129215 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The LARS score is used for assessment of bowel dysfunction after rectal cancer resection.
Study NCT02478775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix (GnRH antagonist)
Description: Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist degarelix will be given subcutaneously.
Study NCT02478775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant FSH
Description: Day-2: Blood samples will again be obtained every 10 minutes for 10 hours. Repeated boluses of exogenous recombinant FSH (rFSH) will be given by IV during this 10 hour visit.
Study NCT02478775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist Cetrorelix will be given subcutaneously.
Study NCT04063930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LOKELMA 5 GM Powder for Oral Suspension
Description: Sodium zirconium cyclosilicate (a hyperkalemia treatment)
Study NCT04063930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Matching placebo
Study NCT02217267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 3 mg/kg dilute in Normal Saline to 50 ml intravenous infusion in 1 hour
Study NCT02217267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01965301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1.5375 suspension
Description: single oral dose
Study NCT01965301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BP1.5375 suspension
Description: single oral dose
Study NCT01965301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BP1.5375 suspension
Description: single oral dose
Study NCT01965301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: single oral dose of Diphenhydramine 50mg
Study NCT01965301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: single oral dose of Diphenhydramine 50mg
Study NCT01965301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: single oral dose of Diphenhydramine 50mg
Study NCT01965301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose
Study NCT01965301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single oral dose
Study NCT01965301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose
Study NCT04306978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CareLink Express RM system
Description: CareLink Express remote monitoring system consists of implantable pacemaker CareLink Express station for implanted Medtronic cardiac devices and provides remote data transmissions
Study NCT04306978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: Follow-up will be provided according to the standard guidelines (HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations; 2008)
Study NCT05148936 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: COVID-19 Testing Mobile Approach 1 (Aim 2)
Description: Implementation of Antigen and PCR testing at mobile test sites - active outreach
Study NCT05148936 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: COVID-19 Testing Mobile Approach 2 (Aim 2)
Description: Implementation of Antigen and PCR testing at mobile test sites - baseline outreach
Study NCT00005945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT03753360 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet-Based Mindfulness Program - Stress Free Now for Healers
Description: Stress Free Now for Healers is an online stress management program developed at Cleveland. It's delivered in 4 components:1Weekly introductions to the concepts and meditation theme are delivered via Web page views or a 5to10-min audio clip2Weekly guided meditations 5-20 min ea.available as embedded/downloadable mp3 on the website or via the Stress Free Now for Healers phone app,which participants are invited to practice at least 4 times each week and to record those practices3Daily articles provide the scientific underpinnings and merits of each week's theme or discuss various cognitive and behavioral strategies,activities,and concepts supporting or related to mindfulness4Daily tips suggesting how to manage stress or incorporate mindfulness in daily activities,including motivational quotes.Participants will have access to a smartphone app with recordings of the 11 guided meditations.Ea. participant will be assigned an e-coach that will communicate with the participant at least weekly.
Study NCT03753360 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Active Control Group - Relaxing Music
Description: The control group will be given a flash drive and a link to a website where they can download several digital recordings of relaxing music and will be instructed to quietly listen to one or more of the recordings for at least 5 minutes every day for 6 weeks.
Study NCT02676648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent online program
Description: The core program includes information developed in earlier research with individuals with type 2 diabetes, now modified for online delivery: very low-carbohydrate diet taught with lectures on video, handouts, quizzes, and surveys. We also teach participants about the importance of physical activity and adequate sleep, in addition to psychological skills (positive affect, mindful eating) intending to help with intervention adherence.
Study NCT00005945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT
Study NCT00005945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study NCT00005945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO
Study NCT00005945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Dose 25 g/m² IV Days 0, 7, 14, given over a period of 15 minutes to 2 hours
Study NCT00005945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given PO
Study NCT00005945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given PO and IT
Study NCT00005945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM
Study NCT02676648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath meter
Description: We will send participants a breath meter to test ketones in their breath, to assess dietary adherence.
Study NCT02676648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: We will send participants text messages, to support intervention adherence.
Study NCT02676648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet-appropriate foods and cookbooks
Description: We will send participants diet-appropriate foods and cookbooks, to support intervention adherence.
Study NCT00005945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO
Study NCT00005945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT05253937 — intervention group
Intervention type: DRUG
Intervention: Epinephrin
Description: The study will enroll acute myocardial infarction patients who suffered from a cardiac arrest in the cardiac catheterization laboratory during percutaneous intervention procedure. Cardiac Resuscitation was performed according to the European Resuscitation Council (ERC) Guidelines. The preferred route of epinephrine administration was through the central venous access (by internal jugular or subclavian vein). Thus, if available, it was the preferred method of medication delivery. However, in cases without central venous access, the route of epinephrine administration (peripheral intravenous or arterial intracoronary) during cardiac arrest was left to the treating physicians.
Study NCT03831178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Description: Participants will take 11 capsules of DHA oil for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
Study NCT03831178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Participants will take 11 capsules of placebo (corn/soy oil blend) for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
Study NCT02225704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 and enzalutamide
Study NCT04069949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib; toripalimab
Description: Stage I: cohort A: sorafenib 400 mg qd+ toripalimab 240 mg d1; q3w cohort B: sorafenib 400 mg bid, toripalimab 240 mg d1; q3w Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39.
Study NCT01663766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: milatuzumab
Description: Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.
Study NCT00005945 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT04082637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness in Body-oriented Therapy
Description: A mind-body intervention designed to teach interoceptive awareness skills for emotion regulation and self-care. Delivered individually in 75 minute sessions once a week for 8 weeks.
Study NCT00477256 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 5 Paper-and-Pencil Questionnaires: All participants will engage in a one-time completion of all measures.
Study NCT03788967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBPM-PI-HBr
Description: TBPM-PI-HBr tablets administered orally.
Study NCT03788967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Antibiotic Therapy for cUTI.
Study NCT03788967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dummy Infusion
Description: Dummy intravenous infusion.
Study NCT03788967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dummy tablets
Description: Dummy tablets orally.
Study NCT01685203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r
Description: Tablet; ABT-450; Capsule; ritonavir
Study NCT01685203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: Tablet
Study NCT01685203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablet
Study NCT00458211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone
Description: Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks
Study NCT04285372 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Side branch protection/ballooning
Description: Side branch protection in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
Study NCT04285372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No side branch protection/ballooning
Description: No intervention on the side branch
Study NCT01202760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Study NCT01202760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2127399
Study NCT01202760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01202760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02911519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Group Psychoeducation
Description: First session: describe the clinical manifestations of schizophrenia, deny myths, and inform on the biological nature of the disorder. Second session: provide updated information regarding pharmacological treatment, their side effects and the importance of adherence to treatment. Third session: Achieving recognition of personal responsibility for the lifestyle, routine, physical care and the risk of addiction; awareness of the importance of self-monitoring of symptoms and the development of cognitive, behavioral and emotional strategies. Fourth Session: To recognize the role of family members in the treatment, the problem of expressed emotions and communication in times of crisis. Fifth Session: To know the rights and duties of patients and their families in the current health care system.
Study NCT02911519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. This is done in consultation of 30 minutes, in which the psychiatrist evaluates the clinical condition of the patient and psychosocial factors that may be affecting, prescribes drugs according to protocols and clinical care and answers questions about the disorder. In the consultation a brochure with information is given about schizophrenia. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
Study NCT02911519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. This is done in consultation of 30 minutes, in which the psychiatrist evaluates the clinical condition of the patient and psychosocial factors that may be affecting, prescribes drugs according to protocols and clinical care and answers questions about the disorder. In the consultation a brochure with information is given about schizophrenia. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
Study NCT00399568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Intravenous acetaminophen 1 g/100 mL
Study NCT03647176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Description: cold snare polypectomy (CSP), which does not include electrocautery to do a polypectomy with a snare